We are pleased to share that GenMark was acquired by Roche Diagnostics in 2021. As part of this new chapter, our social media channels will no longer be active after December 6. We encourage you to follow Roche Diagnostics USA to stay updated with the latest solutions and news related to GenMark.
Info
GenMark Diagnostics is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. GenMark’s ePlex®: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. At GenMark, we’re changing the diagnostics landscape, combining out-of-the-box thinkers and game-changing technology to revolutionize patient care. Our work atmosphere is dynamic, fast-paced, and patient-focused. We encourage teamwork, while reinforcing the importance of individuality, and encouraging an entrepreneurial spirit. GenMark is not just a job – it’s a way of life. We also provide opportunities to volunteer in the community, participate in sports leagues, and enjoy company social events. Culture is the cornerstone of what makes GenMark a special place to work. We are proud to embrace a culture of accountability in the work we do.
- Website
-
http://www.genmarkdx.com
Externer Link zu GenMark Diagnostics
- Branche
- Herstellung medizinischer Geräte
- Größe
- 501–1.000 Beschäftigte
- Hauptsitz
- Carlsbad, CA
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Multiplex Molecular Diagnostics, Medical Devices, Infectious Diseases, Syndromic Testing, Electrochemical Detection, In Vitro Diagnostics, Random and Continuous Access, Multiplex PCR, eSensor, IVD, Patient Centered Care, True Sample-to-Answer Workflow, Patient Safety, Long Term Partner und Data Management
Orte
-
Primär
5964 La Place Ct
Carlsbad, CA 92008, US
-
General-Guisan-Strasse 6
6303 Zug, CH
Beschäftigte von GenMark Diagnostics
Updates
Verbundene Seiten
Ähnliche Seiten
Finanzierung
Letzte Runde
Kapitalerhöhung nach Börsengang70.000.000,00 $